Macrophage polarization in immune-inflammatory diseases with lung damage: The promising therapeutic strategies
https://doi.org/10.47360/1995-4484-2026-12-21
Abstract
The article discusses the role of macrophage polarization in the processes of inflammation and fibrosis. Targeting the polarization of alternatively activated M2 macrophages could be a promising strategy to prevent fibrosis progression. The prospects for the treatment of immune-inflammatory diseases with lung damage, aimed at macrophage functions, are considered, including the possibilities of using the selective neuropilin 2 modulator efzophytimod in systemic sclerosis and sarcoidosis, as well as other diseases.
About the Authors
T. V. Beketova
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation ; V.A. Nasonova Research Institute of Rheumatology ; Moscow Polytechnic University
Russian Federation
Russian Federation
Tatiana V. Beketova
121359, Moscow, Marshala Timoshenko str., 19, building 1A
115522, Moscow, Kashirskoye Highway, 34A
107023, Moscow, Bolshaya Semyonovskaya str., 38
E. I. Shchepikhin
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Evgeniy I. Shchepikhin
107564, Moscow, Yauzskaya Alley, 2
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Lidia P. Ananyeva
115522, Moscow, Kashirskoye Highway, 34A
References
1. Yona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system – The unaccounted years. Front Immunol. 2015;6:328. doi: 10.3389/fimmu.2015.00328
2. Wu S, Zhao S, Hai L, Yang Z, Wang S, Cui D, et al. Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases. Autoimmun Rev. 2025;24(7):103820. doi: 10.1016/j.autrev.2025.103820
3. Gerasimova EV, Popkova TV. Macrophage functional disorders in rheumatoid arthritis and atherosclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(4):486-493 (In Russ.). doi: 10.14412/1995-4484-2018-486-493
4. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Anatomy of a discovery: M1 and M2 macrophages. Front Immunol. 2015;6:212. doi: 10.3389/fimmu.2015.00212
5. Cox N, Pokrovskii M, Vicario R, Geissmann F. Origins, biology, and diseases of tissue macrophages. Annu Rev Immunol. 2021;39:313-344. doi: 10.1146/annurev-immunol-093019-111748
6. Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Mueller M, Wormley FL Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83(12):4513-4527. doi: 10.1128/IAI.00935-15
7. Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb Symp Quant Biol. 2013;78:105-116. doi: 10.1101/sqb.2013.78.020321
8. Mussbacher M, Derler M, Basilio J, Schmid JA. NF-kappaB in monocytes and macrophages – An inflammatory master regulator in multitalented immune cells. Front Immunol. 2023;14:1134661. doi: 10.3389/fimmu.2023.1134661
9. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440. doi: 10.1002/jcp.26429
10. Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-195. doi: 10.1111/imm.12910
11. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 2012;122:787-795. doi: 10.1172/JCI59643
12. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW. Role of Kruppellike factors in leukocyte development, function, and disease. Blood. 2010;116(22):4404-4414. doi: 10.1182/blood-2010-05-285353
13. Rőszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediat Inflamm. 2015;2015:816460. doi: 10.1155/2015/816460
14. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483. doi: 10.1146/annurev.immunol.021908.132532
15. Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156(1):9-18. doi: 10.1016/j.clim.2014.10.008
16. Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y, et al. Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via Toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol. 2020;72(1):166- 178. doi: 10.1002/art.41052
17. Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol. 2011;89(1):130- 142. doi: 10.1038/icb.2010.70
18. Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 2000;204(1):19-28. doi: 10.1006/cimm.2000.1687
19. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173(7):781-792. doi: 10.1164/rccm.200509-1518OC
20. Wynn TA, Barron L. Macrophages: Master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30(3):245-257. doi: 10.1055/s-0030-1255354
21. Nelson DE, Olszewski MA. Editorial: Exploring the molecular mechanisms that regulate macrophage polarization. Front Immunol. 2025;16:1599215. doi: 10.3389/fimmu.2025.1599215
22. Bain CC, MacDonald AS. The impact of the lung environment on macrophage development, activation and function: Diversity in the face of adversity. Mucosal Immunol. 2022;15:223-234. doi: 10.1038/s41385-021-00480-w
23. Osterholzer JJ, Chen GH, Olszewski MA, Zhang YM, Curtis JL, Huffnagle GB, et al. Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. Am J Pathol. 2011;178(1):198-211. doi: 10.1016/j.ajpath.2010.11.006
24. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35. doi: 10.1186/1742-2094-10-35
25. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184(5):569-581. doi: 10.1164/rccm.201010-1719OC
26. Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: A retrospective, multicentre cohort study. Lancet Respir Med. 2019;7(6):497-508. doi: 10.1016/S2213-2600(18)30508-3
27. Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(1):74-81. doi: 10.1164/rccm.202003-0669OC
28. Meziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018;51(3):1702120. doi: 10.1183/13993003.02120-2017
29. Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med. 2017;214(8):2387-2404. doi: 10.1084/jem.20162152
30. Isshiki T, Vierhout M, Naiel S, Ali P, Yazdanshenas P, Kumaran V, et al. Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Biochem Pharmacol. 2023;211:115501. doi: 10.1016/j.bcp.2023.115501
31. Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infection Immun. 2011;79:1915-1926. doi: 10.1128/IAI.01270-10
32. Giles DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, Ponath G, Pitt D, et al. Myeloid cell plasticity in the evolution of central nervous system autoimmunity. Ann Neurol. 2018;83(1):131- 141. doi: 10.1002/ana.25128
33. Xu J, Ganguly A, Zhao J, Ivey M, Lopez R, Osterholzer JJ, et al. CCR2 signaling promotes brain infiltration of inflammatory monocytes and contributes to neuropathology during cryptococcal meningoencephalitis. mBio. 2021;12(4):e0107621. doi: 10.1128/mBio.01076-21
34. Dhupar R, Powers AA, Eisenberg SH, Gemmill RM, Bardawil CE, Udoh HM, et al. Orchestrating resilience: How neuropilin-2 and macrophages contribute to cardiothoracic disease. J Clin Med. 2024;13(5):1446. doi: 10.3390/jcm13051446
35. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002;12(1):13-19. doi: 10.1016/s1050-1738(01)00140-2
36. Harman JL, Sayers J, Chapman C, Pellet-Many C. Emerging roles for neuropilin-2 in cardiovascular disease. Int J Mol Sci. 2020;21:5154. doi: 10.3390/ijms21145154
37. Islam R, Mishra J, Bodas S, Bhattacharya S, Batra SK, Dutta S, et al. Role of neuropilin-2-mediated signaling axis in cancer progression and therapy resistance. Cancer Metastasis Rev. 2022;41(3):771-787. doi: 10.1007/s10555-022-10048-0
38. Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics. 2000;70:211-222. doi: 10.1006/geno.2000.6381
39. Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 1997;19:547-559. doi: 10.1016/S0896-6273(00)80371-2
40. Immormino RM, Lauzier DC, Nakano H, Hernandez ML, Alexis NE, Ghio AJ, et al. Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol. 2018;315(2):L202-L211. doi: 10.1152/ajplung.00067.2018
41. Aung NY, Ohe R, Meng H, Kabasaw T, Yang S, Kato T, et al. Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages. PLoS One. 2016;11:e0147358. doi: 10.1371/journal.pone.0147358
42. Dhupar R, Jones KE, Powers AA, Eisenberg SH, Ding K, Chen F, et al. Isoforms of neuropilin-2 denote unique tumor-associated macrophages in breast cancer. Front Immunol. 2022;13:830169. doi: 10.3389/fimmu.2022.830169
43. Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol. 2018;68-69:355-365. doi: 10.1016/j.matbio.2018.03.015
44. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012;287(15):11629- 11641. doi: 10.1074/jbc.M111.338673
45. Larkin KA, Zafra I, Golden A. Copa-1 mutants experience heightened endoplasmic reticulum stress sensitivity in a C. elegans COPA syndrome model. MicroPubl Biol. 2023;2023:10.17912/micropub. biology.000696. doi: 10.17912/micropub.biology.000696
46. Simchoni N, Vogel TP, Shum AK. COPA syndrome from diagnosis to treatment: A clinician’s guide. Rheum Dis Clin North Am. 2023;49(4):789-804. doi: 10.1016/j.rdc.2023.06.005
47. Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: Survival patterns in a population-based cohort. J Clin Med. 2021;10(21):4830. doi: 10.3390/jcm10214830
48. Nasonov EL, Ananyeva LP, Belevsky AS. Interstitial lung diseases and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2025-119-128
49. Campitiello R, Soldano S, Gotelli E, Hysa E, Montagna P, Casabella A, et al. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review. Autoimmun Rev. 2024;23(10):103637. doi: 10.1016/j.autrev.2024.103637
50. Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11(1):e1004005. doi: 10.1371/journal.pcbi.1004005
51. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol. 2002;26(5):549-557. doi: 10.1165/ajrcmb.26.5.4683
52. Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis. 2018;77(12):1842-1845. doi: 10.1136/annrheumdis-2018-213648
53. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. doi: 10.1186/ar3066
54. Gerasimova EV, Bogatyreva AI, Kirichenko TV, Popkova TV, Shayakhmetova RU, Ananyeva LP, et al. Inflammatory response of cultured macrophages in treatmentnaive patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):176-182 (In Russ.). doi: 10.47360/1995-4484-2025-176-182
55. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438-449. doi: 10.1378/chest.14-1120
56. Ying Z, Elyse EL, Yinping F, Shanshan D, Huiping L, Robert PB. Clinical characteristics of sarcoidosis patients in the United States versus China. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(3):209- 216. doi: 10.36141/svdld.v34i3.5727
57. Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84-95. doi: 10.1165/rcmb.2018-0053OC
58. Shamaei M, Mortaz E, Pourabdollah M, Garssen J, Tabarsi P, Velayati A, et al. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum Immunol. 2018;79(1):63-69. doi: 10.1016/j.humimm.2017.10.009
59. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99-106. doi: 10.1038/nm1332
60. Wojtan P, Mierzejewski M, Osińska I, Domagała-Kulawik J. Macrophage polarization in interstitial lung diseases. Cent Eur J Immunol. 2016;41(2):159-164. doi: 10.5114/ceji.2016.60990
61. Standiford TJ. Macrophage polarization in sarcoidosis: An unexpected accomplice? Am J Respir Cell Mol Biol. 2019;60(1):9-10. doi: 10.1165/rcmb.2018-0298ED
62. Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145-1150. doi: 10.1183/09031936.00195010
63. Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol. 2011;178(3):1279-1286. doi: 10.1016/j.ajpath.2010.11.065
64. Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary fibrosis and progressive pulmonary fibrosis in a prospective registry of interstitial lung diseases in Eastern Siberia. Life (Basel). 2023;13(1):212. doi: 10.3390/life13010212
65. Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and prognosis of progressive pulmonary fibrosis: A literature review. Pulm Ther. 2025;11(3):347-363. doi: 10.1007/s41030-025-00302-5
66. Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. doi: 10.1183/13993003.02571-2021
67. Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database. Respir Investig. 2024;62(4):702-709. doi: 10.1016/j.resinv.2024.05.005
68. Peng D, Li J, Li Y, Bai L, Xiong A, He X, et al. MMP14high macrophages orchestrate progressive pulmonary fibrosis in SR-Aginduced hypersensitivity pneumonitis. Pharmacol Res. 2024;200:107070. doi: 10.1016/j.phrs.2024.107070
69. Wang J, Zhang L, Luo L, He P, Xiong A, Jiang M, et al. Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discov. 2022;8(1):38. doi: 10.1038/s41420-022-00831-x
70. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi: 10.1002/art.34562
71. Lamprecht P, Gross WL. Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S49-S51.
72. Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, et al. B lymphocyte maturation in Wegener’s granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis. 2006;65(7):859-864. doi: 10.1136/ard.2005.044909
73. Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM. T cellmacrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432. doi: 10.3389/fimmu.2014.00432
74. Capraru D, Müller A, Csernok E, Gross WL, Holl-Ulrich K, Northfield J, et al. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener’s granulomatosis. Clin Immunol. 2008;127(2):144-150. doi: 10.1016/j.clim.2007.12.004
75. Beketova TV. Microscopic polyangiitis associated with antineutrophil cytoplasmic antibodies: Clinical features. Terapevticheskii arkhiv. 2015;87(5):33-46 (In Russ.). doi: 10.17116/terarkh201587533-46
76. Casal Moura M, Tandon YK, Hartman TE, Ryu JH, Baqir M. Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Chest CT patterns and correlation with survival. Semin Arthritis Rheum. 2025;73:152726. doi: 10.1016/j.semarthrit.2025.152726
77. Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, et al. Interstitial lung disease and ANCA-associated vasculitis: A retrospective observational cohort study. Rheumatology (Oxford). 2011;50(11):2035-2043. doi: 10.1093/rheumatology/ker236
78. Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCAassociated vasculitis: From pathogenesis to diagnosis. Clin Kidney J. 2015;8(3):343-350. doi: 10.1093/ckj/sfv020
79. Falk RJ, Terrell RS, Charles LA. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115-4119. doi: 10.1073/pnas.87.11.4115
80. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol. 1994;95(2):244-250. doi: 10.1111/j.1365-2249.1994.tb06518.x
81. Charles LA, Falk RJ, Jennette JC. Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. J Leukoc Biol. 1992;51(1):65-68. doi: 10.1002/jlb.51.1.65
82. Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44(7):1698-1706. doi: 10.1002/1529-0131(200107)44:7<1698::AIDART294>3.0.CO;2-J
83. O’Brien EC, Abdulahad WH, Rutgers A, Huitema MG, O’Reilly VP, Coughlan AM, et al. Intermediate monocytes in ANCA vasculitis: Increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies. Sci Rep. 2015;5:11888. doi: 10.1038/srep11888
84. Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA, et al. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. JCI Insight. 2017;2(2):e87379. doi: 10.1172/jci.insight.87379
85. Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauciimmune necrotizing GN. Clin J Am Soc Nephrol. 2015;10(1):54- 62. doi: 10.2215/CJN.03230314
86. Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2020;35(2):283-291. doi: 10.1093/ndt/gfy300
87. O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol. 2016;27(9):2906-2916. doi: 10.1681/ASN.2015050511
88. Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, et al.; Limburg Renal Registry. Urinary soluble CD163 and disease activity in biopsy-proven ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(12):1740-1748. doi: 10.2215/CJN.07210520
89. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al.; European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 2002;61(1):80-89. doi: 10.1046/j.1523-1755.2002.00089.x
90. de Souza AWS, van Timmeren M, Sanders JS, Stegeman C, Heeringa P, Kallenberg CGM, et al. M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis. Arthritis Res Ther. 2017;19(1):100. doi: 10.1186/s13075-017-1310-4
91. Matsuda S, Kotani T, Kuwabara H, Suzuka T, Kiboshi T, Fukui K, et al. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease. Rheumatology (Oxford). 2021;60(10):4643-4653. doi: 10.1093/rheumatology/keab064
92. Vegting Y, Vogt L, Anders HJ, de Winther MPJ, Bemelman FJ, Hilhorst ML. Monocytes and macrophages in ANCA-associated vasculitis. Autoimmun Rev. 2021;20(10):102911. doi: 10.1016/j.autrev.2021.102911
93. Ohlsson SM, Linge CP, Gullstrand B, Lood C, Johansson A, Ohlsson S, et al. Serum from patients with systemic vasculitis induces alternatively activated macrophage M2c polarization. Clin Immunol. 2014;152(1-2):10-19. doi: 10.1016/j.clim.2014.02.016
94. Vegting Y, Jongejan A, Neele AE, Claessen N, Sela G, Prange KHM, et al. Infiltrative classical monocyte-derived and SPP1 lipid-associated macrophages mediate inflammation and fibrosis in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2025;40(7):1416-1427. doi: 10.1093/ndt/gfae292
95. Hilhorst M, Kok HM, Broekhuizen R, van Paassen P, van Breda Vriesman P, Goldschmeding R, et al.; Limburg Renal Registry. Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2015;30(8):1291-1299. doi: 10.1093/ndt/gfv088
96. Gallo JR, Froullet C, Varizat A, Calvo RA, Pisoni C, Cosatti M, et al. Clinical and imaging pulmonary manifestations in IgG4- related disease. J Clin Rheumatol. 2025;31(2):47-52. doi: 10.1097/RHU.0000000000002160
97. Furukawa S, Moriyama M, Miyake K, Nakashima H, Tanaka A, Maehara T, et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep. 2017;7:42413. doi: 10.1038/srep42413
98. Chinju A, Moriyama M, Kakizoe-Ishiguro N, Chen H, Miyahara Y, Haque ASMR, et al. CD163+ M2 macrophages promote fibrosis in IgG4-related disease via Toll-like receptor 7/interleukin-1 receptor-associated kinase 4/NF-κB signaling. Arthritis Rheumatol. 2022;74(5):892-901. doi: 10.1002/art.42043
99. Hu M, Yao Z, Xu L, Peng M, Deng G, Liu L, et al. M2 macrophage polarization in systemic sclerosis fibrosis: Pathogenic mechanisms and therapeutic effects. Heliyon. 2023;9(5):e16206. doi: 10.1016/j.heliyon.2023.e16206
100. Bahram Yazdroudi F, Malek A. Reducing M2 macrophage in lung fibrosis by controlling anti-M1 agent. Sci Rep. 2025;15(1):4120. doi: 10.1038/s41598-024-76561-0
101. Redente EF, Keith RC, Janssen W, Henson PM, Ortiz LA, Downey GP, et al. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol. 2014;50(4):825-837. doi: 10.1165/rcmb.2013-0386OC
102. Choi YJ, Kim MJ, Lee YJ, Choi M, Shim WS, Park M, et al. Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors. Theranostics. 2025;15(3):875-893. doi: 10.7150/thno.100970
103. Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the progression of skin inflammation, fibrosis, and vascular injury by blockade of the CX3 CL1/ CX 3 CR1 pathway in experimental mouse models of systemic sclerosis. Arthritis Rheumatol. 2019;71(11):1923-1934. doi: 10.1002/art.41009
104. Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, et al. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019;21(1):290. doi: 10.1186/s13075-019-2074-9
105. Stenström M, Nyhlén HC, Törngren M, Liberg D, Sparre B, Tuvesson H, Eriksson H, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci. 2016;83(1):52-59. doi: 10.1016/j.jdermsci.2016.04.006
106. Luong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, et al. Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Res Ther. 2018;20(1):46. doi: 10.1186/s13075-018-1534-y
107. Park GT, Kwon YW, Lee TW, Kwon SG, Ko HC, Kim MB, et al. Formyl peptide receptor 2 activation ameliorates dermal fibrosis and inflammation in bleomycin-induced scleroderma. Front Immunol. 2019;10:2095. doi: 10.3389/fimmu.2019.02095
108. Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Miura S, et al. Glycyrrhizin ameliorates fibrosis, vasculopathy, and inflammation in animal models of systemic sclerosis. J Invest Dermatol. 2017;137(3):631-640. doi: 10.1016/j.jid.2016.08.037
109. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;180(1):165- 176. doi: 10.1016/j.ajpath.2011.09.013
110. Sakkas LI. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Des Dev Ther. 2016;10:2723- 2728. doi: 10.2147/DDDT.S99696
111. Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017;76(6):1133- 1141. doi: 10.1136/annrheumdis-2016-210189
112. Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103. doi: 10.1016/j.bcp.2020.114103
113. Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823
114. Toda M, Mizuguchi S, Minamiyama Y, Yamamoto-Oka H, Aota T, Kubo S, et al. Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. J Clin Biochem Nutr. 2018;63(1):58-65. doi: 10.3164/jcbn.17-111
115. Guo Z, Li S, Zhang N, Kang Q, Zhai H. Schisandra inhibit bleomycin-induced idiopathic pulmonary fibrosis in rats via suppressing M2 macrophage polarization. BioMed Res Int. 2020; 2020:5137349. doi: 10.1155/2020/5137349
116. Wang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, et al. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization. Cell Death Dis. 2020;11(2):136. doi: 10.1038/s41419-020-2329-z
117. Codullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, et al. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J Control Release. 2019;310:198-208. doi: 10.1016/j.jconrel.2019.08.015
118. Burkart C, Seikkula M, Eide L, Paz S, Chu D, Polizzi C, et al. ATYR1923 modulates the inflammatory response in experimental models of interstitial lung disease. Am J Respir Crit. Care Med. 2019;199:A2421. doi: 10.1164/AJRCCM-CONFERENCE.2019.199.1_MEETINGABSTRACTS.A2421
119. Ghazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM, et al. Tocilizumab in patients with systemic sclerosisassociated interstitial lung disease: A systematic review and metaanalysis. Ann Am Thorac Soc. 2024;21(2):328-337. doi: 10.1513/AnnalsATS.202301-056OC
120. Zongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: Insights from a prospective IgG4-related disease registry. Ther Adv Chronic Dis. 2021;12:20406223211028776. doi: 10.1177/20406223211028776
121. Akiyama M, Hayashi Y, Suzuki K, Takeuchi T, Kaneko Y. Successful treatment of IgG4-related disease with tocilizumab monotherapy. Autoimmun Rev. 2023;22(4):103296. doi: 10.1016/j.autrev.2023.103296
122. Ong J, Brown S, Gilbertson M, Grigoriadis G, Simpson I, Vilcassim S, et al. Two cases of refractory IgG4-related disease successfully treated with tocilizumab. Ann Hematol. 2022;101(7):1593-1594. doi: 10.1007/s00277-022-04787-x
123. Rey-Gallardo A, Escribano C, Delgado-Martín C, RodriguezFernández JL, Gerardy-Schahn R, Rutishauser U, et al. Polysialylated neuropilin-2 enhances human dendritic cell migration through the basic C-terminal region of CCL21. Glycobiology. 2010;20(9):1139-1146. doi: 10.1093/glycob/cwq078
124. Rey-Gallardo A, Delgado-Martín C, Gerardy-Schahn R, Rodríguez-Fernández JL, Vega MA. Polysialic acid is required for neuropilin-2a/b-mediated control of CCL21-driven chemotaxis of mature dendritic cells and for their migration in vivo. Glycobiology. 2011;21:655-662. doi: 10.1093/glycob/cwq216
125. Förster S, Chong YE, Siefker D, Becker Y, Bao R, Escobedo E, et al. Development and characterization of a novel neuropilin-2 antibody for immunohistochemical staining of cancer and sarcoidosis tissue samples. Monoclon Antib Immunodiagn Immunother. 2023;42(5):157-165. doi: 10.1089/mab.2023.0007
126. Siefker D, Xu Z, Ferrer M, Yu E, Guy L, Rauch K, et al. Efzofitimod: A novel therapeutic candidate for SSc-ILD. Eur Respir J. 2023;62(Suppl 67):PA419. doi: 10.1183/13993003.congress-2023.PA419
127. Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881-890. doi: 10.1016/j.chest.2022.10.037
128. Obi ON, Baughman RP, Crouser ED, Julian MW, Locke LW, Chandrasekaran A, et al. Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis. ERJ Open Res. 2025;11(1):00536-2024. doi: 10.1183/23120541.00536-2024
Review
For citations:
Beketova T.V., Shchepikhin E.I., Ananyeva L.P. Macrophage polarization in immune-inflammatory diseases with lung damage: The promising therapeutic strategies. Rheumatology Science and Practice. 2026;64(1):12-21. (In Russ.) https://doi.org/10.47360/1995-4484-2026-12-21
Views:
241
JATS XML
Email this article 